Changing of Prostate Specific Antigen Value in Patients With Covid-19

• Sponsor: Saglik Bilimleri Universitesi (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05009186
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 18
• Patients Per Site Per Month: 5.6

Study Details

Study Description

Brief Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Condition or Disease	Intervention/Treatment	Phase
Covid19; Prostate Specific Antigen	Other: PSA value	N/A

Detailed Description

Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 100 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: We measured PSA value during and after Covid-19 infectionWe measured PSA value during and after Covid-19 infection
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Changing of PSA With Covid-19
• Actual Study Start Date: Apr 1, 2020
• Anticipated Primary Completion Date: Oct 1, 2021
• Anticipated Study Completion Date: Oct 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Other: Covid-19 group We will measure the PSA value during and after Covid-19 infection in the same group via paired simple t test	Other: PSA value; We measure PSA value during and after covid-19 infection

Outcome Measures

Primary Outcome Measures

1. PSA value [2 months]

   prostate specific antigen

Secondary Outcome Measures

1. Ferritin, CRP [2 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 45 Years to 70 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Male patients (>45 and <70 years of age) positive PCR test results were included in the study

Exclusion Criteria:

• The patients <45 and >70 years of age who described lower urinary tract symptoms who had urinary tract infection who a history of prostate biopsy and previous high level of PSA who history of prostatitis were excluded.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Omer Gokhan Doluoglu	Ankara	Altindag	Turkey	06100

Sponsors and Collaborators

• Saglik Bilimleri Universitesi

Investigators

• Principal Investigator: Omer G Doluoglu, Associate Professor, Ankara Training and Research Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Omer Gokhan Doluoglu, Ankara Training and Research Hospital, Saglik Bilimleri Universitesi
• ClinicalTrials.gov Identifier: NCT05009186
• Other Study ID Numbers: PSA
• First Posted: Aug 17, 2021
• Last Update Posted: Aug 17, 2021
• Last Verified: Aug 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Omer Gokhan Doluoglu, Ankara Training and Research Hospital, Saglik Bilimleri Universitesi: Covid-19; Prostate cancer; Prostate Specific Antigen
• Additional relevant MeSH terms: COVID-19

Study Results

No Results Posted as of Aug 17, 2021